Literature DB >> 2688778

Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes.

M Gossop1, P Griffiths, B Bradley, J Strang.   

Abstract

This study investigates and compares the responses of 132 opiate addicts to a 10-day or a 21-day in-patient oral methadone withdrawal regime. For both groups, symptom severity (on the Opiate Withdrawal Scale) steadily increased through the methadone withdrawal phase, and peaked near the point of completion of the prescribed drug, declining slowly thereafter. Patients on the 10-day programme reported significantly higher peak withdrawal scores than those on the 21-day programme. Although the proportions who completed detoxification were similar, there was a significantly higher drop-out rate immediately after detoxification for the 10-day group. The possible benefits and handicaps of the two withdrawal schedules are considered and recommendations are proposed for further refinement of the present widely adopted approach.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2688778     DOI: 10.1192/bjp.154.3.360

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  11 in total

Review 1.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

Review 2.  The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Authors:  Kelly E Dunn; Stacey C Sigmon; Eric C Strain; Sarah H Heil; Stephen T Higgins
Journal:  Drug Alcohol Depend       Date:  2011-07-08       Impact factor: 4.492

3.  Drug users in prison.

Authors:  M Farrell; J Strang
Journal:  BMJ       Date:  1994-07-23

4.  A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.

Authors:  Stacey C Sigmon; Kelly E Dunn; Kathryn Saulsgiver; Mollie E Patrick; Gary J Badger; Sarah H Heil; John R Brooklyn; Stephen T Higgins
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

Review 5.  Buprenorphine for managing opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White; Dalitso Mbewe
Journal:  Cochrane Database Syst Rev       Date:  2017-02-21

Review 6.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 7.  Advancing addiction treatment: what can we learn from animal studies?

Authors:  Peter H Wu; Kalynn M Schulz
Journal:  ILAR J       Date:  2012

Review 8.  Biological mechanisms that promote weight regain following weight loss in obese humans.

Authors:  Christopher N Ochner; Dulce M Barrios; Clement D Lee; F Xavier Pi-Sunyer
Journal:  Physiol Behav       Date:  2013-08-01

9.  Extended-release formulation of morphine for subcutaneous administration.

Authors:  T Kim; J Kim; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  [Requirements of a regional medical service for drug addicted patients].

Authors:  Martin Schmidt; Michael V Cranach; Stefan Egger
Journal:  Wien Med Wochenschr       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.